Catalog No.S3041 Synonyms: L-DOPS
Molecular Weight(MW): 213.19
Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
Purity & Quality Control
Choose Selective Adrenergic Receptor Inhibitors
|Description||Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).|
|Features||An artificial amino acid.|
Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline.  Droxidopa is well tolerated.  Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure.  Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. 
|In vivo||The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow. Droxidopa-treated rats also showed a decreased ratio of p-eNOS/eNOS and p-AKT/AKT and increased activity of RhoK in SMA.|
-  Mathias CJ. Clin Auton Res, 2008, 18 Suppl 1, 25-29.
-  Mathias CJ, et al. Clin Auton Res, 2001, 11(4), 235-242.
-  Kaufmann H. Clin Auton Res, 2008, 18 Suppl 1, 19-24.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03229174||Recruiting||Parkinson Disease|Neurogenic Orthostatic Hypotension||William Ondo MD|Lundbeck LLC|The Methodist Hospital System||August 23 2018||Phase 4|
|NCT03446807||Not yet recruiting||Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy||Loma Linda University|H. Lundbeck A/S||April 2018||Phase 2|
|NCT02897063||Recruiting||Autonomic Failure|Pure Autonomic Failure|Multiple System Atrophy|Parkinson Disease|Orthostatic Hypotension||Vanderbilt University Medical Center||September 2016||Phase 1|
|NCT02812147||Recruiting||Parkinson Disease||St. Joseph''s Hospital and Medical Center Phoenix|Arizona State University Tempe||May 2016||Phase 2|
|NCT03173781||Completed||Parkinson''s Disease||Colorado Springs Neurological Associates|H. Lundbeck A/S||April 2016||Not Applicable|
|NCT02586623||Recruiting||Symptomatic Neurogenic Orthostatic Hypotension||Lundbeck Northera Ltd.||February 2016||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.